CLPT ClearPoint Neuro, Inc.

CIK 0001285550 50 ready 8-Ks latest August 3, 2026, 4:05 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing August 3, 2026, 4:05 PM ET

Top materiality 0.80

Event mix earnings ×24 · other_material ×9 · other ×6

Sentiment 26 pos · 4 neg · 20 neu

Latest earnings ▼ miss 2026-Q1

Executive change recent →

Recent 8-K filings for CLPT

Highest-materiality recent filing

ClearPoint Neuro secures up to $110M from Oberland Capital with $33.5M funded at closing

May 12, 2025, 7:59 PM ET debt materiality 0.80 positive item 1.01 item 8.01 item 9.01

Enters note agreement for up to $105M; $30M funded at closing, up to $25M optional second tranche, up to $50M third tranche.
Issues 275,808 shares at $12.69 in registered direct offering for $3.5M gross proceeds.

Read filing →

August 3, 2026, 4:05 PM ET earnings materiality 0.75 negative item 2.02 item 7.01 item 9.01

ClearPoint Neuro Q2 revenue $10.9M (+18% YoY); revises 2026 guidance to $48-52M

Q2 revenue $10.9M (+18% YoY); Biologics & Drug Delivery revenue fell 15% to $4.0M.
May 21, 2026, 4:30 PM ET other material materiality 0.55 neutral item 5.02 item 5.07 item 9.01 ◈ Shareholder Votes ×4

ClearPoint Neuro shareholders approve 1M share increase in 2013 incentive plan; board committees reappointed

Shareholders approved 7th Amended 2013 Incentive Compensation Plan, increasing share pool by 1,000,000 shares to 7,806,250 total.
May 13, 2026, 4:05 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

ClearPoint Neuro Q1 revenue $12.1M (+43% YoY); guides FY2026 $52-56M

Record Q1 revenue of $12.1M; organic device growth 25% YoY; gross margin expanded to 64% from 60%.
March 17, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases ×3

ClearPoint Neuro reports Q4 revenue $10.4M (+34% YoY); FY 2025 revenue $37.0M (+18%); guides FY 2026 $52-56M

Q4 2025 revenue $10.4M including $1.2M from recent IRRAS acquisition; organic growth 19% YoY.
February 5, 2026, 6:59 PM ET M&A materiality 0.55 negative item 9.01

ClearPoint Neuro files financials for acquired IRRAS; IRRAS cash from ops -$11.4M in 2024

IRRAS 2024 operating cash outflow $11.4M; accumulated deficit $105.3M.
January 12, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

ClearPoint Neuro Q4 2025 prelim revenue $10.4M (+20% YoY); FY2026 guidance $54-60M

Q4 2025 preliminary unaudited revenue ~$10.4M, 20% comparable sales growth over Q4 2024, excluding recent IRRA flow acquisition.
January 5, 2026, 6:59 PM ET debt materiality 0.15 neutral item 1.01 item 2.03 ◈ Material Agreements

ClearPoint Neuro enters consent for Swedish subsidiary reorganization under note purchase agreement

Consent dated Dec 29, 2025 with TPC Investments III LP (Oberland affiliate) under the May 12, 2025 Note Purchase Agreement.
November 20, 2025, 6:59 PM ET M&A materiality 0.70 positive item 1.01 item 2.01 item 3.02 item 7.01 item 9.01 ◈ M&A Transactions

ClearPoint Neuro completes acquisition of IRRAS for $5M cash + 1.325M shares

Acquisition closed Nov 20, 2025; IRRAS shareholders received $5M cash and 1.325M CLPT shares.
November 6, 2025, 6:59 PM ET M&A materiality 0.70 positive item 1.01 item 7.01 item 9.01

ClearPoint Neuro to acquire IRRAS for $5M cash + 1.325M shares; combined 2026 rev $54-60M

Total consideration: $5M cash plus 1.325M ClearPoint shares; earnout of 25% of net IRRA flow sales above thresholds.
November 6, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro Q3 rev $8.9M (+9% YoY); narrows FY25 guide $36-38M; acquires IRRAS

Q3 revenue $8.9M, up 9% YoY; cash $38.2M as of Sept 30, 2025.
August 12, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro Q2 revenue record $9.2M (+17% YoY); secures up to $105M note financing

Record Q2 revenue $9.2M, up 17% YoY; neurosurgery segment revenue up 33% to $3.4M.
June 17, 2025, 7:59 PM ET other material materiality 0.45 neutral item 1.01 item 9.01

ClearPoint Neuro signs 132-month lease for ~30,171 sq ft in San Diego life science building

Lease with BRE-BMR SCD LLC for office, R&D, and lab space at $5.95/sq ft initial monthly base rent.
May 23, 2025, 7:59 PM ET other material materiality 0.25 neutral item 5.02 item 5.07 item 9.01

ClearPoint Neuro stockholders approve all six proposals at 2025 annual meeting

All eight director nominees elected; Joseph M. Burnett received 9,980,965 votes for.
May 19, 2025, 7:59 PM ET other material materiality 0.15 neutral item 8.01 item 9.01

ClearPoint Neuro amends director compensation plan with updated cash retainers

Board chair annual retainer increased to $75,000; other members to $45,000 (effective July 1, 2025).
May 13, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro reports record Q1 revenue $8.5M, consumables up 104% YoY

Q1 revenue $8.5M (record), up 11% YoY; consumable product revenue grew 104% to $5.5M.
May 12, 2025, 7:59 PM ET debt materiality 0.80 positive item 1.01 item 8.01 item 9.01

ClearPoint Neuro secures up to $110M from Oberland Capital with $33.5M funded at closing

Enters note agreement for up to $105M; $30M funded at closing, up to $25M optional second tranche, up to $50M third tranche.
February 26, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro reports record FY2024 revenue $31.4M, 31% growth; guides FY2025 $36-41M

FY 2024 revenue $31.4M (+31% YoY); Q4 revenue $7.8M (+14% YoY).
November 7, 2024, 6:59 PM ET other material materiality 0.65 negative item 1.01 item 9.01

ClearPoint Neuro enters $50M ATM equity offering with Stifel

ATM agreement with Stifel allows sale of up to $50M in common stock from time to time.
November 7, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro Q3 revenue $8.1M (+41% YoY); FY guidance reaffirmed

Record quarterly revenue of $8.1M, up 41% YoY; navigation & device revenue $2.9M (+49%).
August 26, 2024, 7:59 PM ET debt materiality 0.55 positive item 7.01 item 9.01

ClearPoint Neuro repays $10M convertible note early, eliminates all debt

On Aug 23, 2024, fully repaid $10M convertible note held by PTC Therapeutics (orig. maturity Jan 2025).
August 7, 2024, 7:59 PM ET earnings materiality 0.78 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro Q2 revenue $7.9M (+32% YoY); raises FY2024 guidance to $30-33M

Record quarterly revenue of $7.9M, up 32% YoY; product revenue more than doubled to $4.9M.
May 16, 2024, 7:59 PM ET other materiality 0.20 neutral item 5.02 item 5.07 item 9.01 ◈ Shareholder Votes ×4

ClearPoint Neuro stockholders re-elect eight directors, approve incentive plan

All eight director nominees elected with over 11.6M votes for each; broker non-votes 6.8M.
May 7, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

ClearPoint Neuro Q1 revenue $7.6M (+41% YoY); biologics revenue $4.3M (+61%); cash burn down 32%

Record quarterly revenue of $7.6M, up 41% YoY; biologics/drug delivery revenue up 61% to $4.3M.
March 12, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases ×2

ClearPoint Neuro Q4 revenue $6.8M (+32% YoY); FY2023 revenue $24M (+17%); reaffirms 2024 guidance $28M-$32M

Q4 2023 revenue $6.8M, up 32% YoY; full-year revenue $24.0M, up 17% YoY.
March 1, 2024, 6:59 PM ET other material materiality 0.65 neutral item 1.01 item 9.01

ClearPoint Neuro prices $15M public offering of 2.3M shares at $6.50

Offering of 2,307,694 shares of common stock at $6.50 per share; underwriters have 30-day option for 346,154 additional shares.
January 8, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

ClearPoint Neuro reports Q4 2023 preliminary revenue $6.8M (+32% YoY); guides FY2024 revenue $28-32M

Preliminary Q4 revenue $6.8M, up 32% YoY; biologics/drug delivery revenue $4.1M (+76% YoY).
November 9, 2023, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

ClearPoint Neuro Q3 revenue $5.8M (+12% YoY); biologics & drug delivery up 55% to $3.5M

Revenue $5.8M, +12% YoY; biologics & drug delivery $3.5M (+55%) driven by preclinical services.
August 8, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

ClearPoint Neuro Q2 revenue record $6.0M (+14% YoY); biologics growth 40%; reaffirms FY guide $25-27M

Record Q2 revenue $6.0M, up 14% YoY; biologics & drug delivery revenue $3.4M (+40%).
August 1, 2023, 7:59 PM ET debt materiality 0.40 neutral item 1.01 item 9.01 ◈ Material Agreements

ClearPoint Neuro amends debt agreement to appoint PTC as collateral agent and transition to SOFR

PTC Therapeutics appointed successor collateral agent under the Securities Purchase Agreement, replacing Petrichor.
May 25, 2023, 7:59 PM ET other material materiality 0.60 positive item 5.03 item 5.07 item 9.01 ◈ Shareholder Votes ×4◈ Governance Changes

ClearPoint Neuro shareholders approve reduction of authorized shares from 200M to 90M

Authorized common stock reduced from 200M to 90M shares; 98.7% of votes cast in favor.
May 22, 2023, 7:59 PM ET other materiality 0.10 neutral item 8.01 item 9.01

ClearPoint Neuro amends director compensation plan effective May 22, 2023

Board approved revisions to non-employee director compensation plan; prior version dated May 21, 2022.
May 11, 2023, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

ClearPoint Neuro Q1 revenue $5.4M (+8% YoY); biologics/drug delivery +24%; reaffirms FY23 guidance $25-27M

Revenue $5.4M (+8% YoY); biologics and drug delivery revenue $2.7M (+24% YoY) drove growth.
March 3, 2023, 6:59 PM ET leadership materiality 0.45 neutral item 1.01 item 5.02 item 9.01

ClearPoint Neuro amends CEO, CFO, COO employment agreements with enhanced severance and equity vesting

Amendments extend severance benefits to CEO Burnett, CFO D'Alessandro, and COO Sabra upon company non-renewal of term.
March 1, 2023, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

ClearPoint Neuro reports Q4 2022 revenue $5.2M (+21% YoY); full-year revenue $20.6M (+26% YoY)

Q4 2022 revenue $5.2M, up 21% YoY; full-year revenue $20.6M, up 26% YoY (record).
January 11, 2023, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 7.01 item 9.01 ◈ Earnings Releases ×2

ClearPoint Neuro Q4 revenue $5.2M (+21%); FY2022 revenue $20.6M (+26%) missing guidance; FY2023 guide $25-27M

Preliminary Q4 2022 revenue $5.2M (+21% YoY); biologics/drug delivery $2.3M (+37%); functional neurosurgery $2.3M (+7%).
December 14, 2022, 6:59 PM ET other materiality 0.20 neutral item 5.03 item 9.01 ◈ Governance Changes

ClearPoint Neuro adopts Fourth Amended and Restated Bylaws with universal proxy, enhanced disclosure rules

Board adopted amended bylaws effective Dec. 14, 2022, to comply with SEC universal proxy rules and recent Delaware law changes.
November 8, 2022, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

ClearPoint Neuro Q3 revenue $5.1M (+13% YoY); reaffirms FY2022 guidance

Revenue of $5.1M, up 13% YoY; gross margin improved to 72% from 66%.
November 7, 2022, 6:59 PM ET other materiality 0.50 neutral item 1.01 item 9.01 ◈ Material Agreements

ClearPoint Neuro signs 10-year lease for 19,462 sq ft Carlsbad facility

Lease commences June 1, 2023; ends May 31, 2033; base rent $36,977.80/month.
September 20, 2022, 7:59 PM ET leadership materiality 0.55 positive item 5.02 item 7.01 item 9.01 ◈ executive_change

ClearPoint Neuro appoints Mazin Sabra as COO; details employment terms

Mazin Sabra named COO, effective October 10, 2022, reporting to CEO Joe Burnett.
August 9, 2022, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro Q2 revenue record $5.2M (+52% YoY); reaffirms 2022 guidance

Quarterly revenue $5.2M (record), up 52% YoY; biologics/drug delivery revenue $2.4M +73%.
June 6, 2022, 7:59 PM ET other material materiality 0.35 neutral item 8.01 item 9.01

ClearPoint Neuro nullifies authorized share decrease after proxy statement error

At May 24, 2022 Annual Meeting, stockholders approved decreasing authorized shares from 200M to 80M.
May 26, 2022, 7:59 PM ET other materiality 0.30 neutral item 5.03 item 5.07 item 9.01

ClearPoint Neuro stockholders approve authorized share reduction from 200M to 80M

Authorized common shares reduced from 200M to 80M via Certificate of Amendment.
May 23, 2022, 7:59 PM ET other material materiality 0.20 neutral item 8.01 item 9.01

ClearPoint Neuro amends director compensation plan; sets retainers and equity grants

Board chair annual retainer set at $75,000; other members receive $40,000.
May 19, 2022, 7:59 PM ET regulatory materiality 0.30 neutral item 3.01

ClearPoint Neuro receives Nasdaq non-compliance notice, cures by reconstituting committees

Nasdaq notified ClearPoint Neuro on May 19, 2022 of non-compliance with audit and compensation committee independence rules due to Matthew Klein, M.D. not being independent.
May 11, 2022, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro Q1 revenue $5.0M, up 25% YoY; raises FY2022 guidance to $21-22M

Record quarterly revenue of $5.0M, a 25% increase vs Q1 2021.
March 1, 2022, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

ClearPoint Neuro reports Q4 revenue $4.3M (+15%) and record 2021 revenue $16.3M (+27%)

Q4 2021 revenue $4.3M (+15% YoY); full-year revenue $16.3M (+27% YoY), seventh consecutive year of growth.
February 15, 2022, 6:59 PM ET earnings materiality 0.65 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro reports Q4 rev $4.3M (+15% YoY); FY2021 rev record $16.3M (+27% YoY); 2022 guidance $20-22M

Q4 2021 revenue $4.3M, up 15% YoY; functional neurosurgery products $2.1M (+37%), biologics/drug delivery $1.7M (+10%).
February 14, 2022, 6:59 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01 ◈ executive_change

ClearPoint Neuro COO Peter Piferi resigns, will serve as interim head of regulatory under consulting agreement

Peter G. Piferi voluntarily resigned as COO effective Feb 18, 2022; not due to any disagreement with management.
December 17, 2021, 6:59 PM ET other materiality 0.10 neutral item 5.03 item 9.01

ClearPoint Neuro adopts amended bylaws with exclusive forum provision

Board adopted Third Amended and Restated Bylaws effective December 16, 2021.
November 9, 2021, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro Q3 revenue $4.6M record, up 30% YoY; reaffirms FY guidance

Record revenue $4.6M (+30% YoY); biologics/drug delivery $2.1M (+39%).

Executive changes

Appointed

Mazin Sabra

Chief Operating Officer

CLPT · ClearPoint Neuro, Inc.

Effective: 2022-10-10
Filed: September 20, 2022, 7:59 PM ET

Mr. Sabra will join the Company as Chief Operating Officer, commencing on October 10, 2022

Departed

Peter G. Piferi

Chief Operating Officer

CLPT · ClearPoint Neuro, Inc.

Effective: 2022-02-18
Filed: February 14, 2022, 6:59 PM ET

Peter G. Piferi voluntarily resigned from his position as the Chief Operating Officer of ClearPoint Neuro, Inc. (the “Company”) and is separating from the Company, effective as of February 18, 2022

Appointed

Linda M. Liau

Director

CLPT · ClearPoint Neuro, Inc.

Effective: 2021-11-02
Filed: November 2, 2021, 7:59 PM ET

On November 2, 2021, the Board of Directors (the “ Board ”) of ClearPoint Neuro, Inc. (the “ Company ”) increased the size of the Board from seven to eight members, and, with the recommendation of the Corporate Governance and Nominating Committee of the Board, appointed Linda M. Liau, MD, PhD, MBA to fill the newly created directorship, effective immediately.

Appointed

Lynnette C. Fallon

Director

CLPT · ClearPoint Neuro, Inc.

Effective: 2021-07-15
Filed: July 15, 2021, 7:59 PM ET

appointed Lynnette C. Fallon to fill the newly created directorship, effective immediately.

Earnings & guidance

2026-Q1 EPS reported -$0.32 vs consensus -$0.27 ▼ miss (-20.7%) filing →

Materiality & sentiment trend

Max materiality 0.80 · Median 0.65 · Most common event earnings

26 positive 4 negative 20 neutral

source · CLPT on sec.gov